CV Sciences Past Earnings Performance

Past criteria checks 0/6

CV Sciences has been growing earnings at an average annual rate of 33.7%, while the Personal Products industry saw earnings growing at 3.8% annually. Revenues have been declining at an average rate of 28% per year.

Key information

33.7%

Earnings growth rate

38.4%

EPS growth rate

Personal Products Industry Growth6.6%
Revenue growth rate-28.0%
Return on equity-115.8%
Net Margin-16.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How CV Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0HRT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2416-390
30 Jun 2416-390
31 Mar 2416-3100
31 Dec 2316390
30 Sep 23161100
30 Jun 23160100
31 Mar 2316-2110
31 Dec 2216-10130
30 Sep 2217-16161
30 Jun 2219-15181
31 Mar 2220-15201
31 Dec 2120-16211
30 Sep 2120-16271
30 Jun 2121-19271
31 Mar 2121-20282
31 Dec 2024-22313
30 Sep 2029-20264
30 Jun 2036-18225
31 Mar 2047-12256
31 Dec 1954-17356
30 Sep 1959-7345
30 Jun 1960-2394
31 Mar 19550363
31 Dec 184810222
30 Sep 18418211
30 Jun 18334200
31 Mar 18250180
31 Dec 1721-5170
30 Sep 1717-14161
30 Jun 1714-15151
31 Mar 1712-16151
31 Dec 1611-14141
30 Sep 1610-12161
30 Jun 1611-11171
31 Mar 1611-11161
31 Dec 1512-12171
30 Sep 1512-14201
30 Jun 1510-14182
31 Mar 1510-4161
31 Dec 1410-1131
30 Sep 148651
30 Jun 147541
31 Mar 144-331
31 Dec 132-221

Quality Earnings: 0HRT is currently unprofitable.

Growing Profit Margin: 0HRT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0HRT is unprofitable, but has reduced losses over the past 5 years at a rate of 33.7% per year.

Accelerating Growth: Unable to compare 0HRT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0HRT is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (10.8%).


Return on Equity

High ROE: 0HRT has a negative Return on Equity (-115.79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/11/27 02:34
End of Day Share Price 2024/08/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CV Sciences, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pablo ZuanicCantor Fitzgerald & Co.
Michael GrondahlNorthland Capital Markets
Michael LaveryPiper Sandler Companies